Latest Headlines

  1. Vector BioMed And Muni Seva Ashram Partner To Bring CAR-T Cell Therapy To Rural India 6/25/2025

    This collaboration positions Vector BioMed as the preferred and exclusive CVDMO partner for KCHRC's cell therapy program, helping expand affordable CAR-T cancer treatment to underserved populations.

  2. AGC Biologics Expands Cell Therapy Development Operations To Asia To Serve Growing Market Need 6/25/2025

    Today, we announced we will commence cell therapy process development and clinical manufacturing services on July 1, 2025, at AGC Inc.’s Yokohama Technical Center, marking the latest step in the global expansion of the company’s Global Cell and Gene Technologies Division. The improved geographical footprint allows AGC Biologics to better serve customers requiring autologous and allogeneic products across all markets, with cell therapy manufacturing now available in three continents (Milan, Italy – Longmont, Colorado, U.S. – Yokohama, Japan).  

  3. Bionova Scientific Expands Capacity And Enters Advanced Therapies Market 6/18/2025

    Bionova Scientific, a contract development and manufacturing organization (CDMO), is entering the advanced therapy manufacturing space.

  4. Nanoform Starts Pivotal Human Bioequivalence Studies Of Nanoenzalutamide 6/12/2025

    Nanoform Finland Plc, the medicine performance-enhancing company, today announced that it had started pivotal relative bioequivalence studies of Nanoenzalutamide, the nanocrystalline-enabled enzalutamide tablet formulation, a potential alternative to the amorphous solid dispersion (ASD) used in XTANDI® (enzalutamide) [1], the number one prescribed androgen receptor inhibitor [2] approved to treat prostate cancer.

  5. CDMO Bora Pharmaceuticals Procures New Aseptic Filling And Closing System From AST 5/29/2025

    AST, a leading provider of flexible drug product manufacturing solutions, has announced the placement of its advanced isolated GENiSYS C fill-finish system with Bora Pharmaceuticals, a premier international contract development and manufacturing organization (CDMO). The flexible, multi-format system will be placed in their 87,000-square-foot clinical-to-commercial drug product manufacturing facility in Baltimore, Maryland.

  6. Australia Delivers Certainty For US Biotechs In 2025: Avance Clinical Offers Fast Start-Up, Regulatory Predictability, And R&D Rebates 5/28/2025

    As regulatory uncertainty grows in the United States, US biotechs are increasingly looking to Australia as a stable and predictable launchpad for early-phase clinical trials. With its globally accepted regulatory framework, accelerated timelines, and 43.5% R&D rebate, Australia offers a compelling advantage — and Avance Clinical, Australia’s leading early-phase specialist CRO, is delivering the GlobalReady solution to help biotechs de-risk, conserve capital and accelerate their programs.

  7. Cellular Origins And 3P innovation Collaborate To Accelerate Industrialisation Of CGT Manufacturing 5/21/2025

    Cellular Origins, a TTP Company, focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), today announced a collaboration with 3P innovation, a leading engineering company and supplier of automated fill-finish equipment.

  8. Meet With Avance Clinical At ASCO 2025 In Chicago 5/20/2025

    Avance Clinical will attend and host a booth at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled from May 30 to June 3, 2025, at McCormick Place in Chicago, Illinois. This premier event brings together oncology professionals from around the world to connect, collaborate, and inspire advancements in cancer care.

  9. Avance Clinical Honored With Frost & Sullivan's 2025 Global Customer Value Leadership Award 5/20/2025

    Frost & Sullivan has named Avance Clinical the recipient of its 2025 Global Customer Value Leadership Award in the biotech contract research organization (CRO) sector, highlighting the company’s outstanding performance in delivering exceptional client value through innovation, service excellence, and technology-enabled trial optimization.

  10. VintaBio Presents Data Demonstrating High-Efficiency AAV Vector Production Using Proprietary VintaProcess™ At 2025 ASGCT Annual Meeting 5/15/2025

    VintaBio, a biotech manufacturer specializing in high-yield, high-purity viral vectors for gene therapy, today presented data further demonstrating the advantages and productivity of its proprietary VintaProcess™ at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting.